#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright Â© 2019 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach."
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Yojana Gadiya"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/conso
# --------------------------------------------------------
 DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns"
 DEFINE NAMESPACE CONSO          AS URL "https://raw.githubusercontent.com/pharmacome/conso/4aa36980578c7d2cff07371abf768f15db89cd11/export/conso-names.belns"
# DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns"
 DEFINE NAMESPACE DOID           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns"
# DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/ec-code.belns"
 DEFINE NAMESPACE EFO            AS URL "https://raw.githubusercontent.com/pharmacome/conso/5d2c2ea6f7112421cc8089a3f021a75ab60bb373/external/efo-names.belns"
# DEFINE NAMESPACE FB             AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/fb-names.belns"
 DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns"
 DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns"
# DEFINE NAMESPACE HP             AS URL "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/hp-names.belns"
 DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/go-names.belns"
# DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/interpro-names.belns"
 DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/conso/f02c6ad4a4791a8ed45448513b9de8c8f1b00c87/external/mesh-names.belns"
# DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/conso/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/mgi-names.belns"
# DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/mirbase-names.belns"
# DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/ncbigene.belns"
# DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/pfam-names.belns"
# DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/conso/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
# DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
# DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
# DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
# DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
 DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"
 DEFINE NAMESPACE NCIT           AS PATTERN "^C\d+$"
 DEFINE NAMESPACE ORPHANET       AS PATTERN "^\d+$"
 DEFINE NAMESPACE IMGTHLA        AS PATTERN "^[A-Z0-9*:]+$"
###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
 DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
# DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
# DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
 DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
# DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
 DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
 DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
# DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
 DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
# DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
# DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############
SET Citation = {"PubMed", "28843454"}

SET Evidence = "Lifestyle and environmental factors are established contributors to risk for MS."
path(MESH:"Life Style") -- path(DOID:"multiple sclerosis")
path(MESH:Environment) -- path(DOID:"multiple sclerosis")

SET Evidence = "There is a positive association between latitude and prevalence of MS at a global level, unexplained by the genetic distribution of high-risk alleles (12)."
#C68642 - Latitude
path(NCIT:C68642) pos path(DOID:"multiple sclerosis")

SET Evidence = "Early work has shown that duration of exposure to sunlight and sunlight intensity are associated with MS risk"
path(MESH:Sunlight) -- path(DOID:"multiple sclerosis")
bp(GO:"response to light intensity") -- path(DOID:"multiple sclerosis")

SET Evidence = "Furthermore, both outdoor work and residence in a high sunlight area have been associated with lower MS mortality rates (17)."
SET MeSHDisease = "Multiple Sclerosis"
path(MESH:Sunlight) -| path(MESH:Mortality)
path(MESH:Work) -| path(MESH:Mortality)
UNSET MeSHDisease

SET Evidence = "Work in the experimental allergic encephalomyelitis (EAE) mouse model has shown beneficial effects of UVR exposure on EAE disease, independent of vitamin D status (20)."
SET Species = "10090"
SET MeSHDisease = "Encephalomyelitis, Autoimmune, Experimental"
a(MESH:"Ultraviolet Rays") -> path(EFO:"experimental autoimmune encephalomyelitis")
composite(a(MESH:"Ultraviolet Rays"), a(MESH:"Vitamin D")) -> path(EFO:"experimental autoimmune encephalomyelitis")
UNSET MeSHDisease
UNSET Species

#####encoding race color??
SET Evidence = "The results demonstrated a significant decrease in risk of MS associated with increasing 25-hydroxyvitamin D among whites."
a(CHEBI:"24,25-Dihydroxyvitamin D") -| path(DOID:"multiple sclerosis")

SET Evidence = "In addition, low vitamin D levels have been implicated in risk for pediatric MS (23) and the prevalence and degree of low vitamin D are comparable between adult and pediatric MS patients (24)."
#477738 - pediatric MS
a(MESH:"Vitamin D") neg path(ORPHANET:477738)

SET Evidence = "Several studies have assessed the role of vitamin D deficiency in the perinatal period (by utilization of biobanks and dried blood spot samples) upon risk for MS, with conflicting results. Swedish studies have looked at the relationship of 25-hydroxyvitamin D levels during gestation (25) and in the neonatal period (26) as it relates to risk of developing MS in these offspring."
#in Pregnancy
a(CHEBI:"24,25-Dihydroxyvitamin D") -- path(DOID:"multiple sclerosis")
SET Anatomy = "neonate stage"
a(CHEBI:"24,25-Dihydroxyvitamin D") -- path(DOID:"multiple sclerosis")
UNSET Anatomy

SET Evidence = "Lower neonatal vitamin D levels were associated with a higher MS risk, with every 25 nmol/L increase in 25-hydroxyvitamin D conferring a 30% reduced risk for MS (27)."
SET Anatomy = "neonate stage"
a(MESH:"Vitamin D") neg path(DOID:"multiple sclerosis")
#every 25 nmol/L
a(CHEBI:"24,25-Dihydroxyvitamin D") -| path(DOID:"multiple sclerosis")
UNSET Anatomy

SET Evidence = "The seroprevalence rates of remote EBV infection are higher in MS as compared to healthy controls, in both adult (31) and pediatric MS patients; however, this association is more striking when studied in the pediatric MS population given the lower rate of seroprevalence in healthy children and adolescents (32,33)."
#seroprevalence - level in blood serum
SET Anatomy = "serum"
path(DOID:"multiple sclerosis") -> path(MESH:"Epstein-Barr Virus Infections")
path(ORPHANET:477738) => path(MESH:"Epstein-Barr Virus Infections")
UNSET Anatomy

SET Evidence = "Evidence suggests that a pediatric MS patientâs antibody response to remote EBV is modified by the HLA-DRB1 allele (35)"
#C52341 - HLA-DRB1 allele (wt)
SET MeSHDisease = "Epstein-Barr Virus Infections"
p(NCIT:C52341) reg bp(MESH:"Antibody Formation")
UNSET MeSHDisease

SET Evidence = "Remote cytomegalovirus (CMV) infection, denoted by the presence of positive serologic anti-CMV IgG, appears to be protective against pediatric MS diagnosis (OR of 0.27; 95% CI 0.11-0.67) (36)."
path(EFO:"Anti-cytomegalovirus IgG measurement") -> path(EFO:"cytomegalovirus infection")
path(EFO:"cytomegalovirus infection") -| path(ORPHANET:477738)
path(EFO:"Anti-cytomegalovirus IgG measurement") -| path(ORPHANET:477738)

####evidence statement doubt?
SET Evidence = "Presence of remote CMV infection and absence of remote EBV infection has also been shown to differentiate children with MS from those with monophasic acquired demyelination (37)."

SET Evidence = "A role for human herpesvirus 6 (HHV-6) has been suggested from studies demonstrating elevated antibodies against HHV-6 in serum of MS patients in addition to the detection of viral DNA within the plaques of MS patients (38)."
SET Species = "9606"
path(EFO:"human herpesvirus 6 seropositivity") -- path(DOID:"multiple sclerosis")
SET Anatomy = "serum"
SET MeSHDisease = "Herpesviridae Infections"
path(DOID:"multiple sclerosis") -> p(MESH:Antibodies)
UNSET MeSHDisease
UNSET Anatomy

SET MeSHDisease = "Multiple Sclerosis"
a(MESH:"DNA, Viral" , loc(NCIT:C95603))
UNSET MeSHDisease

SET Evidence = "Smoking has been shown to increase risk of MS; furthermore, risk increases in a dose-dependent fashion with higher cumulative smoking dose."
path(MESH:Smoking) -> path(DOID:"multiple sclerosis")

SET Evidence = "Despite this, oral tobacco use has not been associated with elevated risk for MS, which suggests that nicotine is not the responsible agent (39)."
a(MESH:"Tobacco, Smokeless") cnc path(DOID:"multiple sclerosis")
a(CHEBI:nicotine) cnc path(DOID:"multiple sclerosis")

SET Evidence = "The frequency of exposure to parental passive smoking was associated with an increased risk for MS (RR 2.12, 95% CI 1.43-3.15)."
#Tobacco Smoke Pollution - passive smoking
a(MESH:"Tobacco Smoke Pollution") -> path(DOID:"multiple sclerosis")

SET Evidence = "Smoking has also been shown to increase the risk of MS disability progression (41)."
SET MeSHDisease = "Multiple Sclerosis"
path(MESH:Smoking) -> path(EFO:"developmental disability")
UNSET MeSHDisease

SET Evidence = "Following this, it was demonstrated that childhood obesity is independently associated with an increased risk of pediatric MS and CIS in girls (but not boys).This risk appears to be dose dependent as well, with higher weight categories being associated with a higher risk (50)."
#CIS - no referce found for this : pediatric clinically-isolated syndrome
#Pediatric Obesity - child obesity
SET Gender = "Female"
path(MESH:"Pediatric Obesity") -> path(ORPHANET:477738)
UNSET Gender
SET Gender = "Male"
path(MESH:"Pediatric Obesity") cnc path(ORPHANET:477738)
UNSET Gender
path(MESH:"Body Weight") -> path(ORPHANET:477738)

SET Evidence = "A more recent study has demonstrated that a higher body mass index (BMI) in early adolescence is a risk factor for pediatric MS in post-pubertal girls (OR=1.60, 95% CI: 1.12-2.27) and boys (OR=1.43, 95% CI: 1.08-1.88) (51)."
SET Gender = {"Female", "Male"}
path(MESH:"Body Mass Index") -> path(ORPHANET:477738)
UNSET Gender

####pathogenic TH17?
SET Evidence = "Though human studies are confounded due to reliance on patient recollection and nonspecific survey-based questionnaires, high salt diet has been shown in EAE models to increase risk of autoimmune disease and drive severity of EAE due to induction of pathogenic TH17 cells (52). One"
SET MeSHDisease = "Encephalomyelitis, Autoimmune, Experimental"
bp(MESH:"Diet, Sodium-Restricted") pos path(EFO:"autoimmune disease")
UNSET MeSHDisease
bp(MESH:"Diet, Sodium-Restricted") -| p(MESH:"Th17 Cells", var("?"))
p(MESH:"Th17 Cells", var("?")) -> path(EFO:"experimental autoimmune encephalomyelitis")
bp(MESH:"Diet, Sodium-Restricted") -| path(EFO:"experimental autoimmune encephalomyelitis")

SET Evidence = "The bacterial milieu within the gastrointestinal tract has a substantial influence on an individualâs immune profile and response â including development of the immune system, protection against pathogens, and maintenance of immune response (57)."
path(MESH:"Gastrointestinal Microbiome") reg a(MESH:"Immune System")
path(MESH:"Gastrointestinal Microbiome") reg path(MESH:Immunity)
path(MESH:"Gastrointestinal Microbiome") reg bp(GO:"immune response")

SET Evidence = "Indeed, pediatric MS case-control studies have demonstrated differences in gut flora (at a taxa-level) between cohorts(61)."
path(ORPHANET:477738) reg path(MESH:"Gastrointestinal Microbiome")

SET Evidence = "MS disease-modifying therapies and vitamin D supplementation have a modulatory effect on the human
gut microbial composition (62)."
a(MESH:"Vitamin D") reg path(MESH:"Gastrointestinal Microbiome")

SET Evidence = "To-date, taking into account the entire human genome, the MHC, located on chromosome 6, comprises the single largest genetic contribution to MS susceptibility. HLA genes encode for cell surface glycoproteins with a primary role in presenting antigenic peptide fragments to T-cells (74)"
p(HGNCGENEFAMILY:"Histocompatibility complex") -> path(DOID:"multiple sclerosis")
g(HGNCGENEFAMILY:"Histocompatibility complex") -> p(MESH:"Membrane Glycoproteins")
p(MESH:"Membrane Glycoproteins") -> bp(GO:"T cell antigen processing and presentation")

SET Evidence = "Deeper investigation revealed these to be part of an HLA haplotype â in particular, the HLA-DRB1*15:01 allele has consistently been shown to be an independent risk factor for MS, particularly in populations of European ancestry, with an odds ratio (OR) of approximately 3 (75)."
g(IMGTHLA:HLA00865) pos path(DOID:"multiple sclerosis")

SET Evidence = "the HLA-DRB1*15:03 allele is a risk factor in African Americans, while the HLA-A*02 allele appears to confer a protective effect against MS, with an OR of approximately 0.6 (79)."
#HLA-A*02
p(IMGTHLA:HLA00870) -> path(DOID:"multiple sclerosis")
p(MESH:"HLA Antigens") -| path(DOID:"multiple sclerosis")

SET Evidence = "Given this, there has been exploration into the idea that genetic variants within the mitochondrial DNA (mtDNA) could play a role in MS risk. Mitochondrial haplogroups have been associated with adult-onset MS (82)."
a(MESH:"DNA, Mitochondrial") -- path(DOID:"multiple sclerosis")

SET Evidence = "Many of the currently-identified haplogroups have SNPs that occur in genes that encode subunits of the oxidative phosphorylation complex - deficiencies of which can result in bioenergetic dysfunction."
bp(MESH:"Oxidative Phosphorylation") pos path(MESH:"Energy Metabolism")

SET Evidence = "Children with HLADRB1*15 alleles were more likely to ultimately meet diagnostic criteria for MS (OR=2.7). This effect was greater in children of European ancestry (OR=3.3). No difference in DRB1*15 allele frequency was found between children with monophasic acute demyelinating syndrome and unaffected controls (84), suggesting that the HLA-DRB1*15 allele is a risk factor for pediatric MS but not monophasic demyelinating events (23)."
p(HGNC:"HLA-DRB1") -- path(DOID:"multiple sclerosis")
SET MeSHDisease = "Demyelinating Diseases"
p(HGNC:"HLA-DRB1") cnc path(DOID:"multiple sclerosis")
UNSET MeSHDisease
p(HGNC:"HLA-DRB1") -> path(ORPHANET:477738)


SET Anatomy = "central nervous system"
SET MeSHDisease = "Multiple Sclerosis"

SET Evidence = "Studies have identified tissue-specific (e.g. within the CNS white matter of MS patients) upregulation of the peptidylargininedeiminase-2 (PAD2) enzyme by way of DNA hypomethylation."
bp(GO:"DNA hypomethylation") -> p(HGNC:PADI2)

SET Evidence = "This upregulation of PAD2 leads to production of a less-stable form of myelin basic protein and subsequent loss
of immune tolerance (89)."
p(HGNC:PADI2) -> p(HGNC:MBP, var("?"))
p(HGNC:MBP, var("?")) -| path(MESH:"Immune Tolerance")
p(HGNC:PADI2) -| path(MESH:"Immune Tolerance")

UNSET MeSHDisease
UNSET Anatomy

SET Evidence = "epigenetic research in MS patients have demonstrated evidence of hypomethylation of genes involved in regulation of immune response and T-cell differentiation âincluding IFNG, FOXP3, IL-13 and IL-17 (91) â ultimately resulting in increased expression of these genes."
#C121521 - hypomethylation
SET MeSHDisease = "Multiple Sclerosis"
g(HGNC:IFNG ,var("NCIT:C121521")) -> g(HGNC:IFNG)
g(HGNC:FOXP3 ,var("NCIT:C121521")) -> g(HGNC:FOXP3)
g(HGNC:IL13 ,var("NCIT:C121521")) -> g(HGNC:IL13)
g(HGNC:IL17A ,var("NCIT:C121521")) -> g(HGNC:IL17A)

p(HGNC:IFNG) reg bp(GO:"immune response")
p(HGNC:FOXP3) reg bp(GO:"immune response")
p(HGNC:IL13) reg bp(GO:"immune response")
p(HGNC:IL17A) reg bp(GO:"immune response")

p(HGNC:IFNG) reg bp(GO:"T cell differentiation")
p(HGNC:FOXP3) reg bp(GO:"T cell differentiation")
p(HGNC:IL13) reg bp(GO:"T cell differentiation")
p(HGNC:IL17A) reg bp(GO:"T cell differentiation")
UNSET MeSHDisease

SET Evidence = "Other studies have demonstrated evidence of hypermethylation in genes involved with immune system regulation (e.g. SHP-1), resulting in reduced genetic expression and a resultant increase in leukocyte-mediated inflammation (92)."
#PTPN6 - SHP - 1
g(HGNC:PTPN6) reg a(MESH:"Immune System")
p(HGNC:PTPN6,pmod(NCIT:C20102)) -| g(HGNC:PTPN6)
SET Cell = "leukocyte"
g(HGNC:PTPN6) -| path(MESH:Inflammation)
p(HGNC:PTPN6,pmod(NCIT:C20102)) -> path(MESH:Inflammation)
UNSET Cell

SET Evidence = "In pediatric MS cohorts, HLA-DRB1 is associated with the EBNA-1 antibody response, suggesting that HLA risk genes have an important influence on the immune response to viral infection (99)."
#EBNA-1 - Epstein-Barr virus nuclear antigen 1
path(ORPHANET:477738) -> composite(p(NCIT:C52341), p(EFO:"Anti-Epstein-Barr virus early antigen IgG measurement"))
SET Disease = "viral infectious disease"
p(HGNCGENEFAMILY:"Histocompatibility complex") -- bp(GO:"immune response")
UNSET Disease

SET Evidence = "It also appears that viral infections may help to shape the early immune response, as early life herpes simplex virus-1 (HSV-1) infection appears to be protective in those who are HLA-DRB1*15 positive (100)."
p(MESH:"Herpesvirus 1, Human") -| p(HGNC:"HLA-DRB1")

SET Evidence = "Smoking greatly increases MS risk in individuals who are positive for the HLA-DRB1*15 allele and negative for the HLA-A*02 allele (OR 13.5) compared to nonsmokers with the same HLA genotype (OR 4.9) (101)"
#C150640 - HLA-A*0201 Negative
SET MeSHDisease = "Smoking"
p(HGNC:"HLA-DRB1") -> path(DOID:"multiple sclerosis")
p(NCIT:C150640) -> path(DOID:"multiple sclerosis")
UNSET MeSHDisease

SET Evidence = "Obesity has been linked to HLA risk alleles, as obese (BMIâ¥27) individuals, who were positive for HLADRB1*
15 and negative for HLA-A*02 exhibited an increased risk of MS (OR 16.2) compared to those with BMI < 27 with the same HLA genotype risk factors (OR 5.1) (103)."
#BMI < 27
SET MeSHDisease = "Obesity"
p(HGNC:"HLA-DRB1") -> path(DOID:"multiple sclerosis")
p(NCIT:C150640) -> path(DOID:"multiple sclerosis")
UNSET MeSHDisease

SET Evidence = "Oral agents (i.e. fingolimod, teriflunomide, dimethyl fumarate) have been approved for relapsing adult MS, and many pediatric patients exhibit a desire for these therapies given the route of administration."
a(PUBCHEM:107970) -| path(EFO:"relapsing-remitting multiple sclerosis")
a(PUBCHEM:54684141) -| path(EFO:"relapsing-remitting multiple sclerosis")
a(PUBCHEM:637568) -| path(EFO:"relapsing-remitting multiple sclerosis")

a(PUBCHEM:107970) -| path(ORPHANET:477738)
a(PUBCHEM:54684141) -| path(ORPHANET:477738)
a(PUBCHEM:637568) -| path(ORPHANET:477738)

a(PUBCHEM:107970) isA path(MESH:"Administration, Oral")
a(PUBCHEM:54684141) isA path(MESH:"Administration, Oral")
a(PUBCHEM:637568) isA path(MESH:"Administration, Oral")

SET Evidence = "Similarly, the data regarding infusion therapies (e.g. natalizumab, rituximab, cyclophosphamide, alemtuzumab) and monoclonal antibody injection therapies (e.g. daclizumab) is limited in regards to safety and efficacy in pediatric MS."
a(PUBCHEM:135314782) -| path(ORPHANET:477738)
a(PUBCHEM:135341754) -| path(ORPHANET:477738)
a(PUBCHEM:2907) -| path(ORPHANET:477738)
a(PUBCHEM:135330159) -| path(ORPHANET:477738)
a(PUBCHEM:46504469) -| path(ORPHANET:477738)

a(PUBCHEM:135314782) isA path(MESH:"Home Infusion Therapy")
a(PUBCHEM:135341754) isA path(MESH:"Home Infusion Therapy")
a(PUBCHEM:2907) isA path(MESH:"Home Infusion Therapy")
a(PUBCHEM:135330159) isA path(MESH:"Home Infusion Therapy")
a(PUBCHEM:46504469) isA p(MESH:"Antibodies, Monoclonal")

SET Evidence = "Along with the potential for accumulating physical disability, symptoms of co-morbid depression (125), fatigue (125), reduced physical activity (126,127), and cognitive dysfunction (128-130) are also highly prevalent."
#for MS and pediatric MS
path(ORPHANET:477738) -- path(EFO:"developmental disability")
path(ORPHANET:477738) -- path(DOID:"mental depression")
path(ORPHANET:477738) -- path(MESH:Fatigue)
path(ORPHANET:477738) -| path(MESH:Exercise)
path(ORPHANET:477738) -- path(DOID:"cognitive disorder")

path(DOID:"multiple sclerosis") -- path(EFO:"developmental disability")
path(DOID:"multiple sclerosis") -- path(DOID:"mental depression")
path(DOID:"multiple sclerosis") -- path(MESH:Fatigue)
path(DOID:"multiple sclerosis") -| path(MESH:Exercise)
path(DOID:"multiple sclerosis") -- path(DOID:"cognitive disorder")
